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Nephrology, Maisonneuve-Rosemont Hospital, Department of Medicine, University of Montreal, Montreal, Quebec, CanadaIntroduction: The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines
for Glomerulonephritis recommend that patients with membranous nephropathy (MN) at risk for pro-
gression receive immunosuppressive therapy (IST), usually after 6 months of observation. A cyclophos-
phamide (CYC) or calcineurin inhibitor (CNI)–based regimen is recommended as first-line IST. However,
the extent to which KDIGO recommendations are adopted in practice remains largely unknown.
Methods: We evaluated prescribing practice among patients with primary MN (diagnosed 2010–2018)
enrolled in the Cure Glomerulonephropathy Network (CureGN) cohort study. We also evaluated the
availability of testing for phospholipase A2 receptor (PLA2R) in the contemporary era.
Results: Among 361 patients (324 adults and 37 children) with MNwho were IST-naïve at biopsy and had at
least 6months of follow-up, 55%of adults and 58%of children initiated IST<6months after biopsy. Of these,
1 in 5 had no indication for (i.e., urine protein-to-creatinine ratio [uPCR] <4 g/g) or an apparent contraindi-
cation to (i.e., an estimated glomerular filtration rate [eGFR] <30 ml/min per 1.73 m2) IST. As first-line IST,
half of treated patients received either CYC (16% of adults; 0% of children) or a CNI (40% and 46%, respec-
tively), whereas 1 in 5 received corticosteroidmonotherapy (20% and 27%, respectively) and 1 in 6 rituximab
(15% and 15%, respectively). More than 80% of surveyed centers had access to PLA2R testing.
Conclusion: These findings suggest that providers are not aware of, or lack confidence in, current KDIGO
guidelines for MN. Treatment patterns observed in this cohort might critically inform the drafting of
planned updates to KDIGO guidelines.
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International Reports (2019) 4, 1725–1734P rimary MN is a leading cause of nephrotic syn-drome in adults worldwide but is much rarer in
children.1,2 The clinical presentation and natural his-
tory of MN are highly variable, with up to one-third of
patients entering remission spontaneously without1725
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decline in kidney function.5,6 The KDIGO clinical prac-
tice guidelines for MN recommend initiation of IST af-
ter 6 months of observation if patients have not entered
remission spontaneously,7 or sooner if severe disease
complications develop. However, it is recommended
that IST be avoided entirely in patients expected to
have a good prognosis without IST (i.e., <4 g/24 hours
of proteinuria) or in those whose disease is already too
advanced (i.e., those with a serum creatinine >3.5 mg/
dl or an eGFR <30 ml/min per 1.73 m2). The KDIGO
guidelines also recommended specific first- and
second-line IST approaches based on limited data
from randomized controlled trials. However, the extent
to which these recommendations regarding the neces-
sity, timing, and choice of IST in MN are adopted in
clinical practice remains unknown.
Because KDIGO guidelines for glomerulonephritis
were published in 2012, understanding of the patho-
physiology and treatment of MN has advanced
considerably, in particular since the discovery that
M-type PLA2R antibodies are implicated in most cases
of primary MN.8–13 Accordingly, based on a recent
KDIGO consensus report, nearly all MN treatment
recommendations will have to be revisited.14 The dis-
covery of anti-PLA2R has also sparked new interest in
B-cell–targeted IST strategies for MN.15,16 However,
contemporary practices with respect to testing for
PLA2R antigen in biopsy specimens and/or PLA2R
antibodies in serum, and prescribing of B-cell–targeted
IST strategies, among patients with biopsy-proven
primary MN, has not to our knowledge been reported.
Recognizing these knowledge gaps, our study aimed
to describe contemporary practice patterns with
respect to the timing and choice of IST in adults and
children with MN enrolled in the CureGN, to compare
observed practice patterns with current KDIGO treat-
ment guidelines, and to determine accessibility to
PLA2R antigen/antibody testing among nephrologists
caring for patients with MN.METHODS
Study Design and Population
CureGN is an ongoing international cohort study17
aiming to enroll 2400 adults and children with mini-
mal change disease, focal segmental glomerulosclerosis,
MN, or IgA nephropathy, diagnosed by kidney biopsy
within the 5 years before study enrollment. Institu-
tionalized patients, those with end-stage renal disease
at screening, or with diabetes, a prior organ/hemato-
poietic transplant, hepatitis B or C, HIV, malignancy, or
systemic lupus erythematosus at time of biopsy, are
excluded. Patients are recruited from 70 sites (65 in the1726United States, 3 in Canada, 1 in Italy, and 1 in Poland)
and are identified either through receiving nephrology
care at one of these sites or through referral from a
primary treating nephrologist in the community.
Enrollment and subsequent annual visits are conducted
in person; interval 4-monthly study visits can be
conducted in person or remotely (i.e., by telephone or
e-mail). Research coordinators conduct all study visits
and enter data, under the supervision of the site clinical
principal investigator.
All children and adults with MN enrolled in Cur-
eGN by June 5, 2018, were considered for study in-
clusion. We restricted our study population to
patients who were naïve to IST before kidney biopsy
so as to focus on patients we were confident were
prescribed IST for management of newly diagnosed
glomerular disease and not another indication. How-
ever, because it is common practice to treat children
with nephrotic syndrome with glucocorticoids (GCs)
empirically before performing a kidney biopsy, we
regarded children who had received a maximum of 6
weeks of GC monotherapy immediately before kidney
biopsy as also being treatment-naïve. All study sub-
jects provided written informed consent. This study
was approved by each institutional review board in
agreement with the Declaration of Helsinki.
Data Collection and Definitions
Immunosuppressive Medications
At study enrollment, data were collected regarding all
ISTs used to treat glomerular disease before study
enrollment, including start and stop dates. Thereafter,
medication lists were updated at each study visit. We
categorized IST as follows: GC alone, CNI-based ther-
apy, CYC-based therapy, rituximab (RTX)-based ther-
apy, mycophenolate mofetil (MMF)–based therapy, or
combination IST. If GCs were prescribed concurrently
with another IST, we considered this to be therapy
based on the other IST. Therapies started within 30
days of one another were considered part of the same
regimen.
Other Demographic, Clinical, and Laboratory
Measures
We defined adults as those$18 years at time of biopsy.
Glomerular disease subtypes were defined according to
their original biopsy report diagnosis. Whenever
available, laboratory values measured between time of
symptom onset and time of enrollment were collected
and recorded. The eGFR was calculated using the
Bedside Schwartz formula in children18 and the
Chronic Kidney Disease–Epidemiology Collaboration
formula in adults.19 There were missing data for race,
uPCR, hematuria, serum albumin, and eGFR (see
Table 1 for frequencies).Kidney International Reports (2019) 4, 1725–1734
Table 1. Characteristics of IST-naïve patients at the time of biopsy
Characteristics
Adults
(n [ 324)
Children
(n [ 37) P
Age at biopsy (yr) 53 (40, 63) 14 (12, 16) <0.001
Follow-up time after biopsy (mo) 33 (18, 56) 23 (10, 33) 0.006
Female 122 (38) 21 (57) 0.02
Race 0.08
Asian 28 (9) 1 (3)
Black/African American 46 (14) 8 (22)
Native American 1 (0) 1 (3)
White/Caucasian 235 (73) 23 (62)
Multiracial 5 (2) 2 (5)
Unknown 9 (3) 2 (5)
Hispanic ethnicity 26 (8) 12 (32) <0.001
uPCR (g/g) 5.9 (3.5, 8.7) 3.0 (1.2, 7.1) 0.005
Unknown 102 (31) 8 (22)
Hematuria ($1þ) 122 (67a) 20 (77a) 0.25
Unknown 141 (44) 11 (30)
Serum albumin (g/dl) 2.6 (2.1, 3.5) 2.2 (1.6, 3.0) 0.005
Unknown 95 (29) 3 (8)
eGFR (ml/min per 1.73 m2) 83 (60, 106) 107 (84, 128) <0.001
Unknown 66 (20) 4 (11)
Thromboembolism before biopsy 16 (5) 1 (3) 0.54
eGFR, estimated glomerular filtration rate; IST, immunosuppressive therapy; uPCR,
urinary protein-to-creatinine ratio.
aAmong those with available urinalysis results from time of kidney biopsy.
Continuous variables are expressed as median (interquartile range). Categorical vari-
ables are expressed as n (%).
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KDIGO clinical practice guidelines for patients with
MN recommended IST if urinary protein excretion
exceeds 4 g/d AND remains at over 50% of the baseline
value AND is not progressively declining, during an
observation period of at least 6 months, but some ex-
ceptions were described.7 If IST is indicated, a 6-month
course of alternating monthly oral/i.v. GC and oral CYC
is recommended; a CNI (cyclosporine or tacrolimus) is
suggested for patients intolerant of, or with contrain-
dications to, CYC.
We explored alignment of treatment practices for
CureGN participants with MN with KDIGO guidelines,
both for the overall cohort (primary analysis) and
among patients who underwent kidney biopsy either
after July 1, 2012, or after July 1, 2013 (i.e., 0 and 12
months, respectively), after the guidelines were pub-
lished (sensitivity analysis). Patients who received a
first-line IST other than CYC or a CNI were considered
to deviate from KDIGO guidelines. Among patients
who initiated IST <6 months following kidney biopsy,
we examined factors that might appropriately or
inappropriately have prompted earlier IST (i.e.,
severity of proteinuria/hypoalbuminemia, severity of
kidney impairment, duration of symptoms >6 months,
development of a thromboembolic event). Patients with
less than 6 months of follow-up between their biopsy
and their most recent study visit were excluded from
these analyses.Kidney International Reports (2019) 4, 1725–1734Survey of Access to PLA2R Testing
A request to complete a survey regarding access to bi-
opsy staining for PLA2R, and serum testing for anti-
bodies to PLA2R,was distributed by e-mail to all CureGN
participating centers (n¼ 70) inMay 2018. A reminder e-
mail was sent in July 2018. CureGN investigators were
asked to complete the survey online. A copy of the sur-
vey is provided in the Supplementary Figure S1.
Statistical Analyses
Descriptive analyses were performed using frequencies
with percentages for categorical variables and medians
with interquartile ranges (IQRs) for continuous vari-
ables. Unadjusted comparisons across groups (adults
vs. children, treated vs. untreated) were made using c2
and Kruskal-Wallis testing, as appropriate. Times from
biopsy to initiation of first-line IST, stratified by IST
regimen, were estimated using the Kaplan-Meier
method. Times from first- to second-line IST, and the
composition of second-line IST strategies, were also
reported. All analyses were conducted using SAS
software (version 9.4; SAS Institute Inc., Cary, NC).
RESULTS
Patient Characteristics
A total of 419 patients (370 adults and 49 children) with
MN had been enrolled in CureGN at time of manuscript
preparation. Forty-six (12%) of these adults and 12
(24%) of these children received IST (other than a
maximum of 6 weeks of corticosteroids, in the case of
children) before kidney biopsy and were excluded
from our study cohort (Figure 1).
Baseline characteristics at time of biopsy for the 361
adults and children who were treatment-naïve at bi-
opsy are presented in Table 1 (Supplementary Table S1
for data of the entire cohort). Median age at biopsy was
53 (IQR, 40–63) years in adults and 14 (IQR, 12–16)
years in children. Female sex was less frequent in
adults (38%) than children (57%), P ¼ 0.02. Most
adults and children self-reported as white. At biopsy,
comparing adults with children, median uPCR was
higher (5.9 vs. 3.0 g/g, P ¼ 0.005), and median eGFR
was lower (83 vs. 107 ml/min per 1.73 m2, P < 0.001).
Non-immunosuppressive Therapy Approaches
in Adults and Children
Among 324 IST-naïve adults, 93 (29%) were receiving
renin-angiotensin-aldosterone system blockade and 76
(23%) were receiving diuretics at time of biopsy. There-
after, 274 (85%) and 208 (64%) ever received renin-
angiotensin-aldosterone system blockade or diuretics,
respectively, after a median of 33 (IQR, 18–56) months
postbiopsy. Among 37 IST-naïve children, 3 (8%) were
receiving renin-angiotensin-aldosterone system blockade1727
Screened (n = 4019)
Ineligible* (n = 669)
- Local diagnosis (n = 223)
- Biopsy report and/or slides unavailable 
(n = 76)
- Patient lives in institutional setting (n = 10)
- ESKD (n = 69)
- Diabetes (n = 181) 
- HIV (n = 21)
- Active malignancy (n = 32)
- Systemic lupus erythematosus (n = 129)
- Biopsy > 5 years ago (n = 103)
Eligibility incomplete (n = 32)
- Solid organ or bone marrow transplant (n = 35) 
- Hepatitis B or C (n = 40)
Eligible for consent (n = 3318)
Not approached* (n = 458)
- Demonstrated past non-compliance/non-
adherence (n = 88)
- Barriers to obtaining informed consent 
(n = 23)
- Not approached per treating physician 
(n = 75)
- Enrolled in NEPTUNE (n = 52)
- Enrolled in another study (n = 7)
- Not eligible per pathology pre-review 
(n = 48)
- Cohort closed (n = 39)
- Other, specify (n = 199)
Approached (n = 2860)
- Waiting for consent (n = 157)
- Did not consent* (n = 342)
• Not interested (n = 173) 
• Too much effort to get to center 
(n = 78)
• Transportation issues (n = 29)
• Child care issues (n = 5)
• Work-related issues (n = 14)
• Financial hardship (n = 4)
• Refused biosamples (n = 24)
• Other, specify (n = 86)
• Did not provide reason (n = 15)Consented (n = 2361)
Completed enrollment visit 
(n = 2175)
- No enrollment visit > 6 months from consent (n = 25)
- Enrolled and later deemed initial eligbility criteria not met (n = 34)
- Central pathology diagnosis (n = 58)
- Withdrawn from study before completing enrollment visit (n = 69)
•
•
Lost to follow-up (n = 22)
Withdrawn: participant choice (n = 32)
• Withdrawn: investigator’s discretion (n = 3)
• Withdrawn: other, specify (n = 12)
Data entry complete (n = 2128)
- Other diagnosis (n = 1709)
• MCD (505)
• FSGS (n = 531)
• IgAN (n = 507)
• IgAV (n = 166)
MN (419)
<18 years old at biopsy (n = 49)
18+ years old at biopsy (n = 370)
- Incomplete/pending data entry (n = 47)
Figure 1. Flowchart of included patients. Data as of June 5, 2018. *Could provide more than 1 reason. ESKD, end-stage kidney disease; FSGS,
focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; MCD, minimal change disease; MN, membranous ne-
phropathy; NEPTUNE, Nephrotic Syndrome Study Network.
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Thereafter, 27 (73%) and 12 (32%) ever received renin-
angiotensin-aldosterone system blockade or diuretics,
respectively, after a median of 23 (IQR, 10–33) months.
IST Approaches in Adults
Among 324 IST-naïve adults at time of kidney biopsy,
244 (75%) initiated IST at any time during a median
follow-up of 33 (IQR, 18–56) months, and 167 (55%) of
the 302 adults with at least 6 months of follow-up after
kidney biopsy had initiated IST within the first 6
months following kidney biopsy (Table 2). The median
time from biopsy to IST initiation was 4.3 months.1728Focusing on any exposure to IST, 176 (54%) of adults
were ever exposed to GC, either alone (8%) or consecu-
tively/concurrently (92%) with other IST (Table 2).
Thereafter, CNIs, RTX, and CYCwere themost frequently
prescribed ISTs (44%, 31%, and 27% exposed, respec-
tively), followed by MMF, adrenocorticotropic hormone,
and azathioprine (10%, 7%, and <1%, respectively).
Single-agent oral GCs were used earliest in the
disease course (median 31 days from kidney biopsy;
IQR, 9–175 days), followed by CNI-based regimens
(Figure 2).
Focusing on first-line IST, CNI-based regimens were
the most frequently prescribed (40% of the 244 treatedKidney International Reports (2019) 4, 1725–1734
Table 2. Exposure to IST among adults and children who were
IST-naïve at time of kidney biopsy
Adults
(n [ 324)
Children
(n [ 37) P
Ever treated
Any IST 244 (75) 26 (70) 0.45
Steroids 176 (54) 21 (57) 0.78
Oral steroids 169 (52) 20 (54) 0.83
I.v. steroids 30 (9) 2 (5) 0.43
Calcineurin inhibitors 142 (44) 16 (43) 0.95
Mycophenolate mofetil 33 (10) 6 (16) 0.26
Cyclophosphamide 87 (27) 1 (3) 0.001
Oral CYC 83 (26) 1 (3) 0.002
I.v. CYC 10 (3) 0 (0) 0.28
Rituximab 102 (31) 6 (16) 0.05
Azathioprine 1 (0) 0 (0) 0.74
ACTH 23 (7) 0 (0) 0.09
RAAS-blockade 274 (85) 27 (73) 0.07
ACE-inhibitors 144 (44) 24 (65) 0.02
Angiotensin receptor blockers 147 (45) 7 (19) 0.002
Diuretics 208 (64) 12 (32) <0.001
Treated in the first 6 months after biopsya Adults
(n ¼ 302)
Children
(n ¼ 31)
Any IST 167 (55) 18 (58) 0.85
Steroids 112 (37) 12 (39) 0.86
Oral steroids 109 (36) 12 (39) 0.77
I.v. steroids 8 (3) 0 (0) 0.36
Calcineurin inhibitors 86 (28) 11 (35) 0.41
Mycophenolate mofetil 10 (3) 4 (13) 0.01
Cyclophosphamide 47 (16) 0 (0) 0.02
Oral CYC 42 (14) 0 (0) 0.03
I.v. CYC 6 (2) 0 (0) 0.43
Rituximab 31 (10) 3 (10) 0.92
Azathioprine 1 (0) 0 (0) 0.75
ACTH 4 (1) 0 (0) 0.52
RAAS-blockade 172 (57) 17 (55) 0.82
ACE-inhibitors 91 (30) 15 (48) 0.04
Angiotensin receptor blockers 82 (27) 2 (6) 0.01
Diuretics 131 (43) 5 (16) 0.003
ACE, angiotensin converting enzyme; ACTH, adrenocorticotropic hormone; CYC,
cyclophosphamide; IST, immunosuppressive therapy; MN, membranous nephropathy;
RAAS, renin-aldosterone-angiotensin system.
aCohort restricted to those with at least 6 months of follow-up.
Categorical variables expressed as n (%).
MM O’Shaughnessy et al.: Membranous Nephropathy Treatment Patterns CLINICAL RESEARCHadults; Table 3). Thereafter, 49 patients (20% of treated
adults) received single-agent GC for at least 30 days as
their first-line IST. Frequency of use as first-line IST
was similar for both RTX and CYC (15% and 16% of
treated adults, respectively). Other ISTs, including
MMF, adrenocorticotropic hormone, and azathioprine,
were much less frequently prescribed as a first-line IST
(4%, 0%, and 0%, of patients, respectively). Overall,
among the 244 adults who ever received IST, only 138
(57%) received either CYC or a CNI. Restricting the
cohort to adults biopsied on or after July 1, 2013, did
not reveal any meaningful differences (102 of 179 pa-
tients, 57%).
Focusing on second-line IST, 118 (48%) of the 244
adults who started a first-line IST ultimatelyKidney International Reports (2019) 4, 1725–1734transitioned to a second-line IST, after a median of 5
months (range, 1–71 months) (Supplementary
Table S2A). The proportion of patients proceeding to
a second-line IST was highest for single-agent GC (71%
of patients), intermediary for CNI-, CYC-, or MMF-
based regimens (48%, 47%, and 50% of patients,
respectively), and lowest for RTX-based regimens (27%
of patients), P < 0.001. Time from initiation of first-line
IST to initiation of second-line IST was shortest for
single-agent GC (median, 68 days; IQR, 35–131 days) or
MMF-based regimens (median, 64 days; IQR, 45–287
days), and longest for CNI-based regimens (median, 328
days; IQR, 135–622 days). To account for differences in
follow-up time between groups, hazards for tran-
sitioning to second-line IST were compared across first-
line IST groups. Comparing with CYC-based regimens,
hazard ratios (HRs) for transitioning to a second-line
IST were significantly higher for single-agent GC
(HR, 3.4; 95% confidence interval, 1.9–6.0) but similar
for other comparator first-line IST strategies: CNI-based
HR 1.0 (95% confidence interval, 0.6–1.7), RTX-based
HR 0.6 (95% confidence interval, 0.3–1.4), and MMF-
based HR 0.9 (95% confidence interval, 0.4–2.4).
With respect to the choice of second-line IST, sub-
stantial variability was evident (Supplementary
Table S2A).
IST Approaches in Children
Among 37 IST-naïve children (allowing inclusion of
children with a maximum of 6 weeks of GC mono-
therapy immediately before kidney biopsy), 26 (70%)
initiated IST at any time during a median follow-up of
23 (IQR, 10–33) months, and 22 (59%) of 31 children
with at least 6 months of follow-up following kidney
biopsy initiated IST within the first 6 months after
kidney biopsy. The median time from biopsy to IST
initiation was 1.9 months.
Focusing on any exposure to IST, 21 (57%) of 37
children were ever exposed to GC, either alone (24%)
or consecutively/concurrently with other treatments
(76%; Table 2). Thereafter, CNIs (43%), MMF (16%),
and RTX (16%) were the most frequently prescribed
ISTs, followed by CYC, adrenocorticotropic hormone,
and azathioprine (3%, <1%, and <1%, respectively).
Single-agent oral GCs were used earliest in the disease
course (median 3 days from kidney biopsy; IQR, 27 to
59 days), followed by RTX- and CNI-based regimens
(Figure 2).
Focusing on first-line IST, CNI-based regimens were
the most frequently prescribed (46% of the 26 treated
children; Table 3). Thereafter, 7 children (27% of
treated children) received at least 30 days of single-
agent GC as first-line IST: 3 had started GC before
kidney biopsy and IST was transitioned to another IST1729
Figure 2. Time to immunosuppressive therapy (IST) initiation after biopsy among adults (a) and children (b) with membranous nephropathy who
were IST-naïve at the time of kidney biopsy. Any IST also includes adrenocorticotropic hormone and azathioprine.
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initiated single-agent GC after confirming a diagnosis of
MN by kidney biopsy. Frequency of use as first-line
IST was higher for RTX than MMF (15% and 8% of
treated children, respectively), whereas CYC, adreno-
corticotropic hormone, and azathioprine were much
less frequently prescribed as first-line IST (<1% of
patients) in children. Overall, among the 26 children
who ever received IST, only 12 (46%) received a CNI or
CYC (none received CYC), as recommended by KDIGO,
as a first-line IST. Restricting the analysis to children
who were biopsied on or after July 1, 2013, did notTable 3. First-line IST in adults and children who were treatment-
naïve at time of kidney biopsy
First therapy n (%)
Days from biopsy
until onset,
median (IQR)
Days from biopsy
until onset,
range
Adults, n ¼ 324
Never received therapya 80 (25) N/A N/A
CNI-based Therapy 98 (30) 88 (18, 202) 2–1700
Steroids alone 49 (15) 31 (9, 175) 0–2049
CYC-based therapy 40 (12) 61 (18, 153) 0–855
Rituximab-based therapy 37 (11) 133 (75, 277) 15–1964
MMF-based therapy 14 (4) 72 (11, 384) 6–1016
Combination of ISTs 6 (2) 69 (26, 132) 14–207
Children, n ¼ 37
Never received therapya 11 (30) N/A N/A
CNI-based therapy 12 (32) 43 (15, 173) 4–324
Steroids alone 7 (19) 3 (27, 59) 30 to 96
Rituximab-based therapy 4 (11) 37 (20, 272) 4–506
MMF-based therapy 2 (5) 57 (13, 100) 13–100
Combination of ISTs 1 (3) 2 (2, 2) 2–2
ACTH, adrenocorticotropic hormone; CNI, calcineurin inhibitor; CYC, cyclophosphamide;
IST, immunosuppressive therapy; MMF, mycophenolate mofetil; N/A, not applicable.
aNever received any of the following therapies: steroids (oral or i.v.), calcineurin in-
hibitors, mycophenolate mofetil, cyclophosphamide (oral or i.v.) rituximab, azathioprine,
ACTH. A new therapy started within 30 days of a previous therapy is considered to start
at the same time.
1730reveal any meaningful differences (11 of 24 children,
46%). Focusing on second-line IST, 7 (27%) of the 26
children who started a first-line IST ultimately transi-
tioned to a second-line IST (Supplementary Table S2B).
Comparison of Patients Treated Versus Not
Treated With IST During the First 6 Months
Following Kidney Biopsy
Restricting the cohort to patients with at least 6 months
of follow-up following kidney biopsy (n ¼ 302 adults
and n ¼ 31 children), we compared characteristics
between patients who did versus did not initiate IST
within the first 6 months following kidney biopsy
(Table 4). Aside from a higher proportion of male in-
dividuals in the treated group (32% vs. 47% female
sex, P ¼ 0.008), adults treated with IST within the first
6 months following kidney biopsy were demographi-
cally similar to adults who were not treated. However,
treated adults had more severe biochemical features of
the nephrotic syndrome, with a higher median uPCR
(7.0 vs. 3.8 g/g; P < 0.001) and a lower median serum
albumin (2.3 vs. 3.2 g/dl; P < 0.001) at time of biopsy.
The proportion of adults with a uPCR 8 to 12 g/g or
>12 g/g at biopsy was also higher in the treated group,
although 21 (17%) patients who received IST earlier
than 6 months following kidney biopsy had a uPCR <4
g/g before IST initiation. The proportion of patients
with an eGFR <30 ml/min per 1.73 m2 was low in both
groups (8 [6%] of treated and 7 [7%] of untreated pa-
tients, P ¼ 0.22). Adults who were treated versus un-
treated within the first 6 months following biopsy were
not any more likely to have had a thromboembolic
event (15 [9%] vs. 11 [8%]; P ¼ 0.80).
In contrast to the adult population, uPCR and serum
albumin levels were very similar among children whoKidney International Reports (2019) 4, 1725–1734
Table 4. Characteristics of adults and children with MN who were IST-naïve at time of kidney biopsy and who had at least 6 months of
follow-up after kidney biopsy, comparing those who were treated versus untreated with IST within the first 6 months following kidney biopsy
Characteristics
Adults (n [ 302) Children (n [ 31)
Treated (n [ 167) Untreated (n [ 135) P Treated (n [ 18) Untreated (n [ 13) P
Age at biopsy (yr) 53 (42, 63) 53 (40, 63) 0.76 15 (11, 16) 14 (12, 15) 0.70
Follow-up time after biopsy (mo) 33 (19, 54) 40 (22, 60) 0.13 23 (13, 32) 30 (28, 38) 0.05
Time from biopsy to IST 1 (0, 3) N/A N/A 2 (0, 3) N/A N/A
Time from symptom onset to IST 5 (3, 8) N/A N/A 1 (0, 1) N/A N/A
More than 6 mo from symptom onset to IST 61 (37) N/A N/A 2 (11) N/A N/A
Female 53 (32) 63 (47) 0.008 9 (50) 9 (69) 0.28
Race 0.70 0.22
Asian 15 (9) 12 (9) 0 (0) 1 (8)
Black/African American 27 (16) 17 (13) 4 (22) 3 (23)
Native American 0 (0) 1 (1) 0 (0) 1 (8)
White/Caucasian 120 (72) 98 (73) 13 (72) 5 (38)
Multiracial 2 (1) 2 (1) 1 (5) 1 (8)
Unknown 3 (2) 5 (4) 0 (0) 2 (15)
uPCR at biopsy (g/g) 7.0 (4.9, 9.6) 3.8 (2.1, 6.0) <0.001 3.3 (1.2, 7.4) 3.4 (1.3, 4.6) 0.60
<4 21 (17) 42 (53) 7 (50) 7 (70)
4–7.9 53 (43) 27 (34) 4 (29) 2 (20)
8–11.9 35 (28) 7 (9) 1 (7) 1 (10)
$12 15 (12) 4 (5) 2 (14) 0 (0)
uPCR before IST onset (g/g) 6.9 (5.0, 9.5) N/A N/A 5.8 (1.0, 8.7) N/A N/A
<4 20 (17) N/A N/A 5 (36) N/A N/A
4–7.9 51 (44) N/A N/A 5 (36) N/A N/A
8–11.9 30 (26) N/A N/A 1 (7) N/A N/A
$12 14 (12) N/A N/A 3 (21) N/A N/A
Hematuria ($1þ) at biopsya 71 (75) 38 (54) 0.04 11 (92) 6 (67) 0.33
Serum albumin at biopsy, g/dl 2.3 (1.9, 3.0) 3.2 (2.5, 4.0) <0.001 2.3 (1.6, 3.0) 2.1 (1.8, 3.0) 0.88
eGFR at biopsy, ml/min per 1.73 m2 81 (57, 103) 88 (62, 108) 0.22 116 (89, 133) 100 (84, 114) 0.52
eGFR at biopsy <30 8 (6) 7 (7) 1 (6) 0 (0)
Thromboembolism
Before biopsy 8 (5) 7 (5) 0.88 0 (0) 0 (0) 0.99
In 6 mo postbiopsyb 7 (4) 4 (3) 0.58 1 (5) 0 (0) 0.39
eGFR, estimated glomerular filtration rate; IST, immunosuppressive therapy; MN, membranous nephropathy; N/A, not applicable; uPCR, urinary protein-to-creatinine ratio.
aAmong those with hematuria data at biopsy.
bAmong those without thromboembolism before biopsy.
Continuous variables are expressed as median (interquartile range). Categorical variables are expressed as n (%).
MM O’Shaughnessy et al.: Membranous Nephropathy Treatment Patterns CLINICAL RESEARCHwere treated versus untreated in the 6 months
following kidney biopsy. Restricting to patients who
were biopsied after July 1, 2012, or July 1, 2013, did
not reveal any meaningful differences in median time
to first IST, the proportion of patients who received IST
within 6 months following kidney biopsy, or the pro-
portion of patients who received either a CYC- or CNI-
based regimen as first-line IST (although fewer patients
received MMF and more received RTX in the more
recent eras), despite overall similar laboratory measures
of disease severity when compared with earlier cohorts
(Supplementary Table S3).
Survey of Access to PLA2R Testing
A total of 31 centers (44%) responded to the survey
between May 22, 2018 and August 21, 2018. They were
all from the United States and Canada. Most (n ¼ 26,
84%) routinely used anti-PLA2R blood testing,
although only 7 of the 26 (27%) performed the testing
locally. The earliest reported introduction date forKidney International Reports (2019) 4, 1725–1734anti-PLA2R blood testing was January 2014. PLA2R
antigen staining by kidney biopsy was also used
routinely in most centers (n ¼ 25, 81%). In contrast to
blood testing, most centers (21 of 25, 84%) performed
this testing locally. The earliest reported introduction
date for PLA2R antigen testing by kidney biopsy was
June 2013.DISCUSSION
In this international cohort of 419 prevalent adults and
children with MN enrolled in CureGN, we identified
frequent and early use of IST and generally poor
alignment with KDIGO clinical practice guidelines.
Among the 361 patients (324 adults and 37 children)
who were treatment-naïve before kidney biopsy, more
than half initiated IST within 6 months after kidney
biopsy, despite KDIGO recommendations to “watch
and wait” for at least 6 months to observe for sponta-
neous remission. Among those patients who ever1731
CLINICAL RESEARCH MM O’Shaughnessy et al.: Membranous Nephropathy Treatment Patternsreceived IST (75% of adults and 70% of children), only
57% of adults and 46% of children received a CYC- or a
CNI-based regimen as first-line IST, despite KDIGO
recommendations to use these agents as first- and
second-line IST, respectively. We further identified GC
monotherapy as first-line IST for MN in a significant
proportion of patients (20% of treated adults and 27%
of treated children), despite proven inefficacy for
MN.20 Not surprisingly, the response rate for GC
monotherapy as first-line IST also appeared to be
poorer than for other ISTs within our cohort (71% of
adults required a second-line agent, with an HR for
requiring transition to a second-line agent of 3.4 when
compared with CYC).
In this cohort, the median time from biopsy to IST
initiation in adults was 4.3 months. When exploring
possible explanations for earlier than recommended use
of IST, we identified a number of findings. Among
adults, 37% of patients who were treated earlier than 6
months following kidney biopsy had reported symp-
toms of nephrotic syndrome for longer than 6 months;
thus, nephrologists might have been satisfied that the
patient had already failed to enter remission sponta-
neously after 6 months of observation. Next, many of
the adults treated earlier than 6 months after kidney
biopsy had heavy proteinuria at the time of kidney
biopsy (40% of treated vs. 14% of untreated patients
had a uPCR of $8 g/g), and serum albumin was also
lower in the treated group (median 2.3 vs. 3.2 g/dl):
thus, severe and symptomatic nephrotic syndrome
might have triggered IST initiation in these patients.
Finally, 9% of patients treated with IST earlier than 6
months following kidney biopsy had experienced a
thromboembolic event before or in the 6 months
following kidney biopsy, representing a strong indi-
cation to initiate IST without delay. Overall, 44% of
the 167 adults treated within the first 6 months after
kidney biopsy had 1 or more identifiable relative
indication for earlier IST initiation (i.e., symptom
duration >6 months, a uPCR $8 g/g, or a thrombo-
embolic event), whereas 30% lacked any of these in-
dications (representing potential deviations from
KDIGO guidelines), and 26% had insufficient data for
evaluation (i.e., missing symptom duration or uPCR
data). Conversely, 20% of adults treated <6 months
after biopsy had no indication for, or a possible
contraindication to, IST initiation according to KDIGO
guidelines (17% had a uPCR <4 g/g at biopsy, and 6%
had an eGFR <30 ml/min per 1.73 m2 at biopsy,
whereas 15% satisfied both these criteria). No signifi-
cant differences between children treated versus un-
treated with IST in the first 6 months following kidney
biopsy were identified, and numbers were too small to1732derive meaningful conclusions regarding guideline
adherence.
Our study is not without limitations. First, because
much of our data came from chart extraction and pa-
tient interview regarding events that happened before
study enrollment, we can only speculate regarding the
exact reasons for earlier use of IST or IST choice.
Although we could extract information regarding
biochemical features of nephrotic syndrome, eGFR, and
thromboembolic events for most patients, laboratory
data were missing for some patients and severity of
symptoms was missing for all patients, hampering our
ability to truly determine the appropriateness of de-
cisions whether and when to treat with IST. Never-
theless, we hypothesize that use of CNIs as first-line
therapy in almost one-third of patients might have
influenced the decision to start IST earlier than rec-
ommended, as CNIs are generally considered safer than
CYC. Indeed, CYC was used rarely in our study pop-
ulation, especially in children, whereas RTX (which, at
the time these patients were treated, had only been
studied in case reports and series) was used more
frequently than expected. It is worth noting, however,
that some of the patients enrolled in CureGN were also
enrolled in the MENTOR study of RTX use in MN.16
Conceivably, in a treatment era that appears to have
moved away from CYC as first-line IST for MN, in favor
of “less toxic” CNI- or RTX-based regimens, a 6-month
waiting period as recommended by KDIGO might be
considered too long for many nephrologists and their
persistently nephrotic patients. Indeed, the experience
of CureGN participants highlights a potential need to
reconsider current guideline recommendations
regarding IST timing and choice. Finally, the influence
of anti-PLA2R antibody levels on decisions regarding
IST necessity and timing requires further exploration:
although we did collect data regarding the general
availability of testing for PLA2R at study sites, we did
not collect data on whether testing was performed, and
how it influenced decision-making, in each of the in-
dividual study participants.
Our study also illuminates understanding of MN
treatment patterns in children, in whom MN is rare and
randomized controlled treatment trials are lacking.21,22
Indeed, treatment recommendations for children with
MN are extrapolated from adult data, despite higher
rates of spontaneous remission, lower rates of PLA2R
positivity,23,24 andmore favorable renal outcomes25,26 in
children compared with adults. Uncertainty with
respect to IST choice in children with MN is reflected in
the wide variety of first-line IST choices observed in this
cohort. Children rarely received CYC, which we hy-
pothesize is due to concerns for toxicity, includingKidney International Reports (2019) 4, 1725–1734
MM O’Shaughnessy et al.: Membranous Nephropathy Treatment Patterns CLINICAL RESEARCHsterility. Further, the lack of discernible differences
between children who were versus were not treated
with IST within the first 6 months following biopsy
suggests that consensus regarding indications for early
treatment with IST in children is lacking. Accordingly,
CureGN is now uniquely positioned to prospectively
monitor outcomes and treatment responses in children
withMN, which in turn can inform future clinical trials.
To conclude, we have described practice patterns
with respect to the timing and choice of IST among a
large cohort of adults and children with biopsy-proven
MN. We report that only half of treated patients
received a CNI- or CYC-based regimen as first-line IST,
that 1 in 5 treated patients received GC monotherapy as
first-line IST, and that RTX was more frequently pre-
scribed than CYC in our patient cohort, representing
apparent major deviations from KDIGO guidelines.
Further, we report that more than half of patients in
our cohort initiated IST <6 months following kidney
biopsy: while many of these patients had an apparent
indication for earlier treatment (i.e., symptoms for more
than 6 months, severe nephrotic syndrome, or a
thromboembolic event), 1 in 5 had an apparent
contraindication to receiving IST (i.e., a uPCR <4 g/g
or an eGFR <30 ml/min per 1.73 m2). We consider these
findings to represent a lack of awareness of, or confi-
dence in, current KDIGO guidelines, factors that should
be considered when updating these guidelines. Finally,
we report widespread access to PLA2R testing among
CureGN investigators and propose that future treat-
ment guidelines incorporate available data regarding
the role of PLA2R testing in determining the necessity
and timing of IST initiation.DISCLOSURE
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